Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun:62:17-23.
doi: 10.1016/j.exphem.2018.03.001. Epub 2018 Mar 7.

PD-1 deficiency augments bone marrow failure in a minor-histocompatibility antigen mismatch lymphocyte infusion model

Affiliations

PD-1 deficiency augments bone marrow failure in a minor-histocompatibility antigen mismatch lymphocyte infusion model

Maile K Hollinger et al. Exp Hematol. 2018 Jun.

Abstract

Although PD-1 blockade has revolutionized cancer immunotherapy, immune-related adverse events (irAEs) present life-threatening complications. Recent reports of aplastic anemia (AA) as irAEs implicate PD-1/PD-L1 as important in preventing immune-mediated destruction of the hematopoietic niche. Infusion of PD-1-deficient (PD-1 knockout [KO]) lymph node (LN) cells into minor-antigen mismatched mice resulted in early mortality, as well as more severe bone marrow (BM) hypoplasia, anemia, and BM microarchitecture disruption in PD-1 KO LN-infused mice relative to mice that received B6 LN cell infusion. Mice that received PD-1 KO LN cells had more CD8+ T-cell infiltration of the BM and greater expansion of H60-specific CD8+ T cells than did their B6 LN-infused counterparts. In the spleen, CD8+ T cells were skewed to an effector memory phenotype, suggesting accelerated differentiation of PD-1 KO T cells. Our data suggest that PD-1 dysregulation has a role in murine BM failure and vigilance in irAE monitoring may be desirable to treat early AA and related cytopenias.

PubMed Disclaimer

Conflict of interest statement

Disclosures

The authors have no financial conflicts of interest.

Figures

Figure 1
Figure 1
PD-1 KO LN infusion induces severe BM failure. (A) Bone marrow (BM) nucleated cell number in TBI (n=2), B6 LN-induced BM failure (n=4), and PD-1 KO LN-induced BM failure (n=8). (B) Neutrophils (NE), white blood cells (WBC), red blood cells (RBC), and platelets (PLT) in the peripheral blood at day 8. (C) Representative H&E staining of the sternums of TBI, B6 LN-induced, and PD-1 KO LN-induced BM failure mice at day 8. Top row: 100× original magnification, with 50-μm scale bars (white bar). Bottom row: 200× original magnification. Capped lined indicate a p-value obtained through unpaired t test. *, p < 0.05; **, p < 0.01.
Figure 2
Figure 2
PD-1 KO LN-infused mice have increased T cell BM infiltration and antigen-specific T cell expansion. (A) Representative flow plots and statistical analyses of CD4+ and CD8+ T cells in the BM of PD-1 KO LN-infused mice. CD4+ and CD8+ T cells were gated on all live BM cells. (B) Representative flow plots and summarized results of H60-specific T cells in the BM of BM failure mice. H60 tetramer-positive cells were gated on live BM cells. (C) Representative flow plots and summarized results of H60-specific T cells in the spleens of BM failure mice. H60 tetramer-positive cells were gated on live splenocytes. Capped lines indicate a p-value obtained through unpaired t-test, while brackets indicate a p-value obtained through multiple comparisons. *, p < 0.05; **, p < 0.01.
Figure 3
Figure 3
CD8+ T cells are terminally differentiated in the BM, while PD-1 KO T cells have accelerated terminal differentiation in the spleen. (A) Representative flow plots and statistical analyses of CD8+ T cell differentiation subsets in the BM of TBI (dark grey), B6 LN-induced BM failure (black), and PD-1 KO LN-induced (light grey) BM failure mice. Cells shown in the flow plots were gated on all live CD8+ T cells. (B) Representative flow plots and statistical analyses of CD8+ T cell differentiation subsets in the spleen. (C) Representative ELISpot wells (Right) showing IFN-γ secretion by splenocytes isolated from TBI only, B6 LN-infused, and PD-1 KO LN-infused mice. Cells were rested overnight at 37°C, 5% CO2 prior to ELISpot development and analysis. Quantification of IFN-γ-positive spots per 105 splenocytes plated (Left). Capped lines indicate a p-value obtained through unpaired t-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

Similar articles

Cited by

References

    1. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, et al. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. Journal of Clinical Oncology. 2010;28:3167–3175. - PMC - PubMed
    1. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Frontiers in Pharmacology. 2017:8. - PMC - PubMed
    1. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol. 2016;2:1346–1353. - PubMed
    1. Makarious D, Horwood K, Coward JIG. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. European Journal of Cancer. 2017;82:128–136. - PubMed
    1. Birnbaum MR, Ma MW, Fleisig S, Packer S, Amin BD, Jacobson M, McLellan BN. Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma. JAAD Case Reports. 2017;3:208–211. - PMC - PubMed

Publication types

MeSH terms

Substances